A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia

Abstract

IncobotulinumtoxinA (Xeomin(®), NT 201), a preparation without accessory (complexing) proteins, has shown comparable efficacy and safety to onabotulinumtoxinA in treating cervical dystonia (CD). This study evaluated the efficacy and safety of repeated incobotulinumtoxinA injections in subjects with CD. Following a ≤20-week placebo-controlled, randomized, double-blind, single-dose main period, subjects could enter a ≤68-week prospective, randomized, double-blind, repeated-dose, flexible-interval (minimum 6 weeks) extension period with 240 U or 120 U of incobotulinumtoxinA (≤5 injections). Outcome measures included the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) and adverse events (AEs). Of 219 subjects completing the main period, 214 were randomized in the extension period to receive incobotulinumtoxinA 240 U (n = 111) or 120 U (n = 103); 169 subjects completed the extension period, with 90 receiving five injection sessions. Both doses of incobotulinumtoxinA provided statistically significant and clinically relevant improvements in mean TWSTRS-Total, -Severity, -Disability, and -Pain scores, from each injection session to respective 4-week follow-up visits. The most frequently reported AE was dysphagia (240 U: 23.4 %; 120 U: 12.6 %), which did not result in any study withdrawals. There was no impact of injection interval on the incidence of AEs (post hoc analysis). A major limitation of this study was the fixed dose design requested by regulatory authorities, which does not reflect clinical practice. However, repeated incobotulinumtoxinA injections (240 or 120 U; flexible intervals) provided sustained efficacy and were well tolerated, with no unexpected safety risks following repeated injections. The incidence of AEs was similar in subjects requiring repeated injections at shorter intervals (≤12 weeks) compared with those treated using longer intervals (>12 weeks).

Figures

Fig. 1

Study design. The maximum duration of the extension period for each individual subject was 68 weeks. aIndividual duration of placebo-controlled period per subject. bTelephone contact 1 week after injection session, follow-up visits 4 and 8 weeks after injection session. cTelephone contacts 1 week after each injection session, follow-up visits 4 weeks after each injection session

Fig. 2

Subject flow diagram

Fig. 3

TWSTRS-Total and subscores at each injection session of the EP and the respective follow-up visits 4 weeks later (ITT population). Mean TWSTRS-Total scores in 240 U dose group (a); mean TWSTRS-Total scores in 120 U dose group (b); mean changes in TWSTRS-Total scores and subscores in 240 U dose group (c); mean changes in TWSTRS-Total scores and subscores in 120 U dose group (d) *p < 0.05; **p < 0.01; ***p < 0.001. Error bars represent standard deviation Numbers of subjects as shown in Fig. 3a and b, with the following exceptions: Injection session 1, 120 U: TWSTRS-Severity and -Disability subscales, n = 101 Injection session 3, 240 U: TWSTRS-Pain subscale, n = 86 Injection session 3, 120 U: TWSTRS-Severity, -Disability, and -Pain subscales, n = 73 EP extension period, ITT intent-to-treat, Pre at each injection session, Post at a follow-up visit 4 weeks after the respective injection session, TWSTRS Toronto Western Spasmodic Torticollis Rating Scale